Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients

Figures & data

Figure 1 Breakdown by age in the ≥70-year age-group.

Table 1 Baseline patient characteristics

	<70 years old (n=1,301)	≥70 years old (n=1,009)
Median age, years (range)	60 (18–69)	77 (70–93)
Male sex (%)	49.2	54.3
Malignancy type, n (%)
Solid tumors	1,089 (83.7)	749 (74.2)
Lymphoma	138 (10.6)	163 (16.2)
Myeloma	74 (5.7)	97 (9.6)
WHO performance status (%)
0	24.3	16.3
1	52.1	52.3
≥2	23.6	31.4
Anemia severity (%)
Grade 1	56.6	59.7
Grade 2	36.5	34.4

Abbreviation: WHO, World Health Organization.

Table 2 Response rates

	<70 years old	≥70 years old	P-value
3 months
Overall response	79.8%	84%	P=0.0181
Lymphoma	77.1%	84%	P=0.2
Myeloma	88.9%	83.9%	P=0.50
Solid tumors	79.5%	84%	P=0.026
6 months
Overall response	86.3%	86.8%	P=0.82
Lymphoma	81.9%	90%	P=0.11
Myeloma	84.9%	81.5%	P=0.75
Solid tumors	87.1%	86.9%	P=0.99

Figure 2 Percentage of patients in the ≥70-year age-group who experienced main adverse events by disease type.

Table 3 Clinically significant adverse events

	<70 years old, %	≥70 years old, %
Totala	17.6	16.4
Thromboembolic eventsb	2.7	4.5
Infectionc	6.6	3
Increased blood pressure	2.1	2.5
Bleeding	2.9	1.7
Influenza-like symptoms	1.5	1
Injection-site reaction	1.4	0.8
Rash	1.1	0.6
Other	8.4	9.6

Notes:

a More than one adverse event may have been reported in individual patients;

b P=0.011;

c P=0.0002.